Antigen presentation by MHC class II molecules

Immunology and Cell Biology

Volumn 75, Issue 1, 1997, Pages 69-81

  Weenink, Sarah M ^a   Gautam, Anand M ^a  

^a Biology and Environment   (Australia)

Author keywords

antigen presentation; CLIP; DM; invariant chain; MHC class II

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; HELPER CELL; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0031055392     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.11     Document Type: Review

References (106)

1. Heemels M-T, Ploegh HL. Generation, translocation and presentation of MHC class 1-restricted peptides. Annu. Rev. Biochem. 1995; 64: 463-91.
2. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-12.
3. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512-8.
4. Brown JH, Jardetzky TS, Gorga JC et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33-9.
5. Brown JH, Jardetzky TS, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 1988: 332: 845-50.
6. Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins. Annu. Rev.Immunol. 1991; 9: 527-65.
7. Chicz RM, Urban RG, Lane WS et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992; 358: 764-8.
8. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptidcs bound to HLA-DR alleles, J. Exp. Med. 1993; 178: 27-47.
9. d. Science 1992; 256: 1817-20.
10. Rudensky AY, Preston-Hurlburt P, Hong S-C, Barlow A, Janeway CAJ. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622-7.
11. Sadegh-Nasseri S, Germain RN. A role for peptide in determining MHC class II structure. Nature 1991; 353: 167-70.
12. Germain RN, Hendrix LR. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 1991: 353: 134-9.
13. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990; 343: 71-4.
14. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992; 360: 474-7.
15. Stebbins CC, Loss GE, Elias CG, Chervonsky A, Sant AJ. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp. Med. 1995; 181: 223-34.
16. Lanzavecchia A, Reid PA, Watts C. Irreversible association of peptides with class II MHC molecules in living cells. Nature 1992; 357: 249-52.
17. Sung E, Jones PP. The invariant chain of murine Ia antigens: Its glycosylation, abundance and subcellular localization. Mol. Immunol. 1981; 18: 899-913.
18. Claesson L, Larhammer D, Rask L, Peterson PA. cDNA clone for the human y chain of class II histocompatibility antigens and its implications for protein structure. Proc. Natl Acad. Sci. USA 1983; 80: 7395-9.
19. Day CE, Jones PP. The gene encoding the Ia antigenassociated invariant chain (Ii) is not linked to the H-2 complex. Nature 1983; 302: 157-9.
20. Richards JE, Pravtcheva DD, Day C, Ruddle FH, Jones PP. Murine invariant chain gene: chromosomal assignment and segregation in recombinant inbred strains. Immunogenetics 1985; 22: 193-9.
21. McMillan M, Frelinger JA, Jones PP, Murphy DB, McDevitt HO, Hood L. Structure of murine Ia antigens: Two-dimensional electrophoretic analyses and high-pressure liquid chromatography tryptic peptide maps of products of the I-A and I-E subregions and an associated invariant polypeptide. J. Exp. Med. 1981; 153: 936-50.
22. Jones PP, Murphy DB, Hewgill D, McDevitt HO. Detection of a common polypeptide chain in I-A and I-E subregion immunoprecipitates. Immunochemistry 1978: 16: 51-60.
23. O'Sullivan DM, Noonan D, Quaranta V. Four Ia invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation. J Exp. Med. 1987; 166: 444-60.
24. Biljmakers M-JE, Benaroch P, Ploegh HL. Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J. Exp. Med. 1994; 180: 623-9.
25. Roche PA, Marks MS, Cresswell P. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991; 354: 392-4.
26. Schreiber KL, Bell MP, Huntoon CJ, Rajagopalan S, Brenner MB, McKean DJ. Class II histocompatibility molecules associate with calnexin during assembly in the endoplasmic reticulum. Int. Immunol. 1994; 6: 101-11.
27. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993; 74: 257-68.
28. Viville S, Neefjes JJ, Lotteau V et al. Mice lacking the MHC class II-associated invariant chain. Cell 1993; 72: 635-48.
29. Arunachalam B, Lamb CA, Cresswell P. Transport propertics of free and MHC class II-associated oligomers containing different isoforms of human invariant chain. Int. Immunol. 1993; 6: 439-51.
30. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 1990; 345: 615-8.
31. Roche PA, Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc. Natl Acad. Sci. USA 1991; 88: 3150-4.
32. Teyton L, O'Sullivan D, Dickson PW et al. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature 1990; 348: 39-44.
33. Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J. Exp. Med. 1994; 180: 1107-13.
34. Freisewinkel IM, Schenk K, Koch N. The segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc. Natl Acad Sci. USA 1993; 90: 9703-6.
35. Busch R, Cloutier I, Sekaly R-P, Hämmerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J. 1996; 15: 418-28.
36. Elliott EA, Drake JR, Amigorena S et al. The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J. Exp. Med. 1994: 179: 681-94.
37. Lotteau V, Teyton L, Pelcraux A et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990; 348: 600-5.
38. Simonsen A, Momburg F, Drexler J, Hämmerling G, Bakke O. Intracellular distribution of the MHC class II molecules and the associated invariant chain (Ii) in different cell lines. Int. Immunol. 1993; 5: 903-17.
39. Chervonsky AV, Gordon L, Sant AJ. A segment of the MHC class II β chain plays a critical role in targeting class II molecules to the endocytic pathway. Int. Immunol. 1994; 6: 973-82.
40. Maric MA, Taylor MD, Blum JS. Endosomal aspartic proteinases are required for invariant-chain processing. Proc. Natl Acad. Sci. USA 1994; 91: 2171-5.
41. Blum JS, Cresswell P. Role of intracellular proteases in the processing and transport of class II HLA antigens. Proc. Natl Acad. Sci. USA 1988; 85: 3975-80.
42. Peterson M, Miller J. Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41. Nature 1992; 357: 596-8.
43. Fineschi B, Arneson LS, Naujokas MF, Miller J. Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41. Proc. Natl Acad. Sci. USA 1995; 92; 10257-61.
44. Sette A, Ceman S, Kubo RT et al. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 1992; 258: 1801-4.
45. Morkowski S, Goldrath AW, Eastman S et al. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates. J Exp. Med. 1995; 182: 1403-13.
46. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995; 378: 457-62.
47. Gautam AM, Pearson C, Quinn V, McDevitt HO, Milburn PJ. Binding of an invariant chain peptide, CLIP, to I-A major histocompatibility complex class II molecules. Proc. Natl Acad. Sci. USA 1995; 92: 335-9.
48. Malcherek G, Gnau V. G. J, Rammensee H-G, Melms A. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J. Exp. Med. 1995; 181: 527-36.
49. Bangia N, Watts TH. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules. Int. Immunol. 1995; 7: 1585-91.
50. Liang MN, Beeson C, Mason K, McConnell HM. Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC. Int. Immunol. 1995; 7: 1397-1404.
51. Sette A, Southwood S, Miller J, Appclla E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allclie polymorphism in class II. J. Exp. Med. 1995; 181: 677-83.
52. Donermeyer DL, Allen PM. Binding to Ia protects an immunogenic peptide from proteolytic degradation. J. Immunol. 1989; 142: 1063-8.
53. Rotzschke O, Falk K. Origin, structure and motifs of naturally processed MHC class II ligands. Curr. Opin. Immunol. 1994; 6: 45-51.
54. Avva RR, Cresswell P. In ivvo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994; 1: 763-74.
55. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215-21.
56. Lee C, McConnell HM. A general model of invariant chain association with class II major histocompatibility complex proteins. Proc. Natl Acad. Sci. USA 1995; 92: 8269-73.
57. Weenink SM, Milburn PJ, Gautam AM. A continuous central motif of invariant chain peptides. CLIP, is essential for binding to various I-A MHC class II molecules. Int. Immunol. 1997; 9 (in press).
58. Urban RG, Chicz RM, Strominger JL. Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J. Exp. Med. 1994; 180: 751-5.
59. Kropshofer H, Vogt AB, Hämmerling GJ. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Natl Acail. Sci. USA 1995; 92: 8313-7.
60. Kropshofer H, Vogt AB, Stern LJ, Hämmerling GJ. Self-release of CLIP in peptide loading of HLA-DR molecules. Science 1995; 270: 1357-9.
61. Neefjcs JJ, Stollorz V, Peters PJ, Geuze HJ, Ploegh HL. The biosynthetic pathway of MHC class II but not class 1 molecules intersects the endocytic route. Cell 1990; 61: 171-83.
62. Mcllins E, Kempin S, Smith L, Monji T, Pious D. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex. J. Exp. Med. 1991; 174: 1607-15.
63. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1994: 1: 595-606.
64. Kelly AP, Monaco JJ, Cho S, Trowsdale J. A new human HLA class II-related locus, DM. Nature 1991; 353: 571-6.
65. Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes arc both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994; 368: 554-8.
66. Morris P, Shaman J, Attaya M et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994; 368: 551-4.
67. Sanderson F, Klcijmccr MJ, Kelly A et al. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC-class II compartments. Science 1994; 266: 1566-9.
68. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995; 82: 155-65.
69. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 1995; 3: 197-205.
70. Sloan VS, Cameron P, Porter G et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995; 375: 802-6.
71. Mellins E, Cameron P, Amaya M et al. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J. Exp. Med. 1994; 179: 541-9.
72. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity 1996; 4: 87-96.
73. Germain RN, Rinker AGJ. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Mature 1993; 363: 725-8.
74. k class II molecules in human APC containing deleted or mutated HLA DM genes. J. Immunol. 1994; 153: 5382-92.
75. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc. Natl Acad. Sci. USA 1982; 79: 175-8.
76. Davidson HW, Watts C. Epitope directed processing of specific antigen by B lymphocytes. J. Cell Biol. 1989; 109: 85-92.
77. Miettinen HM, Rose JK, Mellman I. Fc receptor isoforms exhibit distinct abilities for coated pit localisation as a result of cytoplasmic domain heterogeneity. Cell 1989; 58: 317-27.
78. Harding CV, Geuze HJ. Immunogenic peptides hind to class II MHC molecules in an early lysosomal compartment. J. Immunol. 1993; 151: 3988-98.
79. Davidson HW, Reid PA, Lanzavecchia A, Watts C. Processed antigen binds to newly synthesised MHC class II molecules in antigen-specific B lymphocytes. Cell 1991; 67; 105-16.
80. Harding CV, Roof RW, Unanue ER. Turnover of Iapeptide complexes is facilitated in viable antigen-presenting cells: Biosynthetic turnover of Ia vs. peptide exchange. Proc. Natl Acad. Sci. USA 1989; 86: 4230-4.
81. Buus S, Sette A, Colon SM, Jenis DM, Grey HM. Isolation and characterization of antigen-la complexes involved in T cell recognition. Cell 1986; 47: 1071-7.
82. Jensen PE. Regulation of antigen presentation by acidic pH. J. Exp. Med. 1990; 171: 1779-84.
83. Wettstein DA, Boniface JJ, Rcay PA, Schild H, Davis MM. Expression of a class II major histocompatibility complex (MHC) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH. J. Exp. Med. 1991; 174: 219-28.
84. Jensen PE. Long-lived complexes between peptide and class II major histocompatibility complex are formed at low pH with no requirement for pH neutralisation. J. Exp. Med. 1992; 176: 793-8.
85. Sette A, Southwood S. O'Sullivan D, Gaeta FCA, Sidney J, Grey HM. Effect of pH on MHC class 11-peptide interactions. J. Immunol. 1992; 148: 844-51.
86. Jensen PE. Enhanced binding of peptide antigen to purified class 11 major histocompatibility glycoproteins at acidic pH. J. Exp. Med. 1991; 174: 1111-20.
87. Tulp A, Verwoerd D, Dobberstein B, Ploegh HL, Pieters J. Isolation and characterization of the intracellular MHC class II compartment. Nature 1994; 369: 120-6.
88. Qiu Y, Wandinger-Ness A, Dalke DP, Pierce S. Separation of subcellular compartments containing distinct functional forms of MHC class II. J. Cell. Biol. 1994; 125: 595-605.
89. West MA, Lucocq JM, Watts C. Antigen processing and class II MHC peptide-loading compartments in human lymphoblastoid cells. Nature 1994; 369: 147-51.
90. Rudensky AY, Maric M, Eastman S, Shoemaker L, DeRoos PC, Blum JS. Intracellular assembly and transport of endogenous pecptide-MHC class II complexes. Immunity 1994; 1: 585-94.
91. Amigorena S, Drake JR, Webster P, Mellman I. Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. Nature 1994; 369: 113-9.
92. Kvist S, Wiman K, Claesson L, Peterson PA, Dobberstein B. Membrane insertion and oligomeric assembly of HLA-DR histocompatibility antigens. Cell 1982; 29: 61-9.
93. Adorini L, Appella E, Doria CS, Cardinaux F, Nagy ZA. Competition for antigen presentation in living cells involves exchange of peptides bound by class II MHC molecules. Nature 1989; 342: 800-3.
94. Reid PA, Watts C. Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature 1990; 346: 655-7.
95. Reay PA, Wettstein DA, Davis MM. pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. EMBO J 1992; 11: 2829-39.
96. Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 1990; 249: 1028-30.
97. k complexes: Correlation of the dissociation rate with T-cell responsiveness. Proc. Natl Acad. Sci. USA 1994; 91: 12862-6.
98. Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptideMHC complexes. Nature 1995; 375: 148-151.
99. Schafer PH, Pierce SK. Evidence for dimers of MHC class II molecules in B lymphocytes and their role in low affinity T cell responses. Immunity 1994; 1: 699-707.
100. Scholl PR, Geha RS. MHC class II signalling in B-cell activation. Immunol. Today 1994; 15: 418-22.
101. Herman A, Kappler JW, Marrack P, Pullen AM. Superantigens: Mechanism of T-cell stimulation and role in immune responses. Annu. Rev. Immunol. 1991; 9: 745-72.
102. Kotzin BL, Leung DM, Kappler JW, Marrack P. Superantigens and their potential role in human disease. Adv. Immun. 1993; 54: 99-166.
103. Jardetzky TS, Brown JH, Gorga JC et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994; 368: 711-8.
104. Kim J, Urban RG, Strominger JL, Wiley DC. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 1994; 266: 1870-4.
105. von Bonin A, Ehrlich S, Malcherek G, Fleischer B. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1. Eur. J. Immunol. 1995; 25: 2894-8.
106. Kappler JW, Herman A, Clements J, Marrack P. Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J. Exp. Med. 1992; 175: 387-96.